{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:11:06Z","timestamp":1790421066299,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T00:00:00Z","timestamp":1584748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T00:00:00Z","timestamp":1584748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"INCA and canceropole d'ile de France"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Retrovirology"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Adult T-cell leukemia-lymphoma (ATL) is an aggressive mature lymphoid proliferation associated with poor prognosis. Standard of care includes chemotherapy and\/or the combination of zidovudine and interferon-alpha. However, most patients experience relapse less than 6 months after diagnosis. Allogeneic stem cell transplantation is the only curative treatment, but is only feasible in a minority of cases. We previously showed in a mouse model that Arsenic trioxide (As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub>) targets ATL leukemia initiating cells.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub> consolidation was given in 9 patients with ATL (lymphoma n\u2009=\u20094; acute n\u2009=\u20092; and indolent n\u2009=\u20093), who were in complete (n\u2009=\u20094) and partial (n\u2009=\u20093) remission, in stable (n\u2009=\u20091) and in progressive (n\u2009=\u20091) disease. Patients received up to 8\u00a0weeks of As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub> at the dose of 0.15\u00a0mg\/kg\/day intravenously in combination with zidovudine and interferon-alpha. One patient in progression died rapidly. Of the remaining eight patients, three with indolent ATL subtype showed overall survivals of 48, 53 and 97\u00a0months, and duration of response to As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub> of 22, 25 and 73\u00a0months. The other 5 patients with aggressive ATL subtype had median OS of 36\u00a0months and a median duration of response of 10\u00a0months. Side effects were mostly hematological and cutaneous (one grade 3) and reversible with dose reduction of AZT\/IFN and\/or As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub> discontinuation. The virus integration analysis revealed the regression of the predominant malignant clone in one patient with a chronic subtype.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>These results suggest that consolidation with As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub> could be an option for patients with ATL in response after induction therapy and who are not eligible for allogeneic stem cell transplantation.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12977-020-0513-y","type":"journal-article","created":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T11:02:41Z","timestamp":1584788561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Arsenic trioxide (As2O3) as a maintenance therapy for adult T cell leukemia\/lymphoma"],"prefix":"10.1186","volume":"17","author":[{"given":"Ambroise","family":"Mar\u00e7ais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviva","family":"Witkover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Asnafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Avettand-Fenoel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Delarue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Cheminant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sibon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"de Th\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R. M.","family":"Bangham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2574-3874","authenticated-orcid":false,"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,21]]},"reference":[{"key":"513_CR1","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","volume":"3","author":"A Gessain","year":"2012","unstructured":"Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388.","journal-title":"Front Microbiol"},{"issue":"9","key":"513_CR2","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1182\/blood-2016-09-692574","volume":"129","author":"T Watanabe","year":"2017","unstructured":"Watanabe T. Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells. Blood. 2017;129(9):1071\u201381.","journal-title":"Blood"},{"issue":"3","key":"513_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","volume":"79","author":"M Shimoyama","year":"1991","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984\u20131987). Br J Haematol. 1991;79(3):428\u201337.","journal-title":"Br J Haematol"},{"issue":"24","key":"513_CR4","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","volume":"126","author":"H Katsuya","year":"2015","unstructured":"Katsuya H, Ishitsuka K, Utsunomiya A, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126(24):2570\u20137.","journal-title":"Blood"},{"key":"513_CR5","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","volume":"28","author":"A Bazarbachi","year":"2010","unstructured":"Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28:4177\u201383.","journal-title":"J Clin Oncol"},{"issue":"9","key":"513_CR6","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1182\/blood-2011-07-368233","volume":"119","author":"J Kanda","year":"2012","unstructured":"Kanda J, Hishizawa M, Utsunomiya A, et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood. 2012;119(9):2141\u20138.","journal-title":"Blood"},{"issue":"9","key":"513_CR7","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","volume":"28","author":"K Yamamoto","year":"2010","unstructured":"Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(9):1591\u20138.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"513_CR8","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/bjh.13338","volume":"169","author":"T Ishida","year":"2015","unstructured":"Ishida T, Jo T, Takemoto S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169(5):672\u201382.","journal-title":"Br J Haematol"},{"issue":"1","key":"513_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1182\/blood.V93.1.278","volume":"93","author":"A Bazarbachi","year":"1999","unstructured":"Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1999;93(1):278\u201383.","journal-title":"Blood"},{"issue":"8","key":"513_CR10","first-page":"2849","volume":"96","author":"ME El-Sabban","year":"2000","unstructured":"El-Sabban ME, Nasr R, Dbaibo G, et al. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood. 2000;96(8):2849\u201355.","journal-title":"Blood"},{"issue":"2","key":"513_CR11","first-page":"130","volume":"5","author":"O Hermine","year":"2004","unstructured":"Hermine O, Dombret H, Poupon J, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed\/refractory adult T-cell leukemia\/lymphoma. Hematol J Off J Eur Haematol Assoc EHA. 2004;5(2):130\u20134.","journal-title":"Hematol J Off J Eur Haematol Assoc EHA"},{"issue":"26","key":"513_CR12","doi-asserted-by":"publisher","first-page":"6528","DOI":"10.1182\/blood-2009-03-211821","volume":"113","author":"G Kchour","year":"2009","unstructured":"Kchour G, Tarhini M, Kooshyar M-M, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia\/lymphoma (ATL). Blood. 2009;113(26):6528\u201332.","journal-title":"Blood"},{"issue":"13","key":"513_CR13","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1084\/jem.20101095","volume":"207","author":"H El Hajj","year":"2010","unstructured":"El Hajj H, El-Sabban M, Hasegawa H, et al. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J Exp Med. 2010;207(13):2785\u201392.","journal-title":"J Exp Med"},{"issue":"9","key":"513_CR14","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1073\/pnas.92.9.3963","volume":"92","author":"JM Flaman","year":"1995","unstructured":"Flaman JM, Frebourg T, Moreau V, et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA. 1995;92(9):3963\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"513_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","volume":"27","author":"K Tsukasaki","year":"2009","unstructured":"Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(3):453\u20139.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"32","key":"513_CR16","doi-asserted-by":"publisher","first-page":"52256","DOI":"10.18632\/oncotarget.13665","volume":"8","author":"A Mar\u00e7ais","year":"2017","unstructured":"Mar\u00e7ais A, Waast L, Bruneau J, et al. Adult T cell leukemia aggressivenness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression. Oncotarget. 2017;8(32):52256\u201368.","journal-title":"Oncotarget"},{"issue":"11","key":"513_CR17","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1182\/blood-2010-10-312926","volume":"117","author":"NA Gillet","year":"2011","unstructured":"Gillet NA, Malani N, Melamed A, et al. The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones. Blood. 2011;117(11):3113\u201322.","journal-title":"Blood"},{"issue":"11","key":"513_CR18","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1038\/leu.2017.260","volume":"31","author":"M Artesi","year":"2017","unstructured":"Artesi M, Mar\u00e7ais A, Durkin K, et al. Monitoring molecular response in adult T-cell leukemia by high-throughput sequencing analysis of HTLV-1 clonality. Leukemia. 2017;31(11):2532\u20135.","journal-title":"Leukemia"}],"container-title":["Retrovirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12977-020-0513-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12977-020-0513-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12977-020-0513-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T00:06:55Z","timestamp":1616285215000},"score":1,"resource":{"primary":{"URL":"https:\/\/retrovirology.biomedcentral.com\/articles\/10.1186\/s12977-020-0513-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,21]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["513"],"URL":"https:\/\/doi.org\/10.1186\/s12977-020-0513-y","relation":{},"ISSN":["1742-4690"],"issn-type":[{"value":"1742-4690","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,21]]},"assertion":[{"value":"6 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The local ethic committee approved this study (CNIL: number 1692254 and CPP IRB registration number 000001072) and all surviving patients gave their consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors contributed to paper correction and editing.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interests related to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}